Skip to main content
Top
Published in: Journal of Clinical Immunology 2/2014

01-02-2014 | Original Research

Variable Clinical expressivity of STAT3 Mutation in Hyperimmunoglobulin E Syndrome: Genetic and Clinical Studies of Six Patients

Authors: Ofir Wolach, Taco Kuijpers, Josef Ben-Ari, Ronit Gavrieli, Neta Feinstein-Goren, Marielle Alders, Ben Zion Garty, Baruch Wolach

Published in: Journal of Clinical Immunology | Issue 2/2014

Login to get access

Abstract

Background and purpose

Autosomal dominant Hyper IgE syndrome (AD-HIES) is a rare and complex primary immunodeficiency that affects multiple systems. Mutations in signal transducer and activator of transcription 3 (STAT3) gene cause AD-HIES. These mutations have a dominant-negative effect and the presence of such mutations is associated with a clinical phenotype. We aim to describe genetic and clinical characteristics of patients with AD-HIES in our clinic and to highlight the variability of clinical patterns in the same family.

Methods

We describe six patients, four individuals of the same family and two unrelated patients. All patients were given a clinical score based on disease phenotype according to the National Institute of Health (NIH) score. Mutation analysis of STAT3 was done by PCR amplification of all coding exons followed by bidirectional sequencing using the BigDye kit v1.1 and an ABI3700 genetic analyzer (Applied Biosystems).

Results

All six patients had DNA binding region point mutations: a proband and his three children with p.Phe384Leu mutation, a patient with p.Arg382Trp substitution and a patient with p.Arg382Gln mutation. All of these mutations were previously reported. Patients differed in infectious, immunologic and somatic features. We observed an extreme variability in disease phenotype within the reported family with one genetically affected patient displaying an ‘unaffected’ phenotype.

Conclusions

Although the genetic cause of AD-HIES is known, more studies are required to better understand the possible additional factors that may affect disease expressivity within families and the clinical diversity of the disease.
Literature
1.
go back to reference Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res. 2009;65:32R–7R. Freeman AF, Holland SM. Clinical manifestations, etiology, and pathogenesis of the hyper-IgE syndromes. Pediatr Res. 2009;65:32R–7R.
2.
go back to reference Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol. 2009;21:487–92. Minegishi Y. Hyper-IgE syndrome. Curr Opin Immunol. 2009;21:487–92.
3.
go back to reference Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125:424–32. e428. Woellner C, Gertz EM, Schaffer AA, Lagos M, Perro M, Glocker EO, et al. Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome. J Allergy Clin Immunol. 2010;125:424–32. e428.
4.
go back to reference Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-ige syndrome. N Engl J Med. 2007;357:1608–19. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-ige syndrome. N Engl J Med. 2007;357:1608–19.
5.
go back to reference Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol. 2010;38:32–8. Heimall J, Freeman A, Holland SM. Pathogenesis of hyper IgE syndrome. Clin Rev Allergy Immunol. 2010;38:32–8.
6.
go back to reference Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: Molecular, cellular, and clinical features from a french national survey. Medicine (Baltimore). 2012;91:e1–e19. Chandesris MO, Melki I, Natividad A, Puel A, Fieschi C, Yun L, et al. Autosomal dominant STAT3 deficiency and hyper-IgE syndrome: Molecular, cellular, and clinical features from a french national survey. Medicine (Baltimore). 2012;91:e1–e19.
7.
go back to reference Heimall J, Davis J, Shaw PA, Hsu AP, Gu W, Welch P, et al. Paucity of genotype-phenotype correlations in STAT3 mutation positive hyper IgE syndrome (hies). Clin Immunol. 2011;139:75–84. Heimall J, Davis J, Shaw PA, Hsu AP, Gu W, Welch P, et al. Paucity of genotype-phenotype correlations in STAT3 mutation positive hyper IgE syndrome (hies). Clin Immunol. 2011;139:75–84.
8.
go back to reference Wolach B, Eliakim A, Pomeranz A, Cohen AH, Nusbacher J, Metzker A. Cyclosporin treatment of hyperimmunoglobulin E syndrome. Lancet. 1996;347:67. Wolach B, Eliakim A, Pomeranz A, Cohen AH, Nusbacher J, Metzker A. Cyclosporin treatment of hyperimmunoglobulin E syndrome. Lancet. 1996;347:67.
9.
go back to reference Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65:735–44. Grimbacher B, Schaffer AA, Holland SM, Davis J, Gallin JI, Malech HL, et al. Genetic linkage of hyper-IgE syndrome to chromosome 4. Am J Hum Genet. 1999;65:735–44.
10.
go back to reference Garty BZ, Ben-Baruch A, Rolinsky A, Woellner C, Grimbacher B, Marcus N. Pneumocystis Jirovecii pneumonia in a baby with hyper-IgE syndrome. Eur J Pediatr. 2010;169:35–7. Garty BZ, Ben-Baruch A, Rolinsky A, Woellner C, Grimbacher B, Marcus N. Pneumocystis Jirovecii pneumonia in a baby with hyper-IgE syndrome. Eur J Pediatr. 2010;169:35–7.
11.
go back to reference Davis SD, Schaller J, Wedgwood RJ. Job’s syndrome. Recurrent, “Cold”, staphylococcal abscesses. Lancet. 1966;1:1013–5. Davis SD, Schaller J, Wedgwood RJ. Job’s syndrome. Recurrent, “Cold”, staphylococcal abscesses. Lancet. 1966;1:1013–5.
12.
go back to reference Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62. Minegishi Y, Saito M, Tsuchiya S, Tsuge I, Takada H, Hara T, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62.
13.
go back to reference Renner ED, Torgerson TR, Rylaarsdam S, Anover-Sombke S, Golob K, LaFlam T, et al. STAT3 mutation in the original patient with job’s syndrome. N Engl J Med. 2007;357:1667–8. Renner ED, Torgerson TR, Rylaarsdam S, Anover-Sombke S, Golob K, LaFlam T, et al. STAT3 mutation in the original patient with job’s syndrome. N Engl J Med. 2007;357:1667–8.
14.
go back to reference Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity. 1999;10:39–49. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced th1 activity and development of chronic enterocolitis in mice devoid of STAT3 in macrophages and neutrophils. Immunity. 1999;10:39–49.
15.
go back to reference Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3 is required for il-21-induced secretion of IgE from human naive B cells. Blood. 2008;112:1784–93. Avery DT, Ma CS, Bryant VL, Santner-Nanan B, Nanan R, Wong M, et al. STAT3 is required for il-21-induced secretion of IgE from human naive B cells. Blood. 2008;112:1784–93.
16.
go back to reference Wolach B, Gavrieli R, Roos D, Berger-Achituv S. Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections. J Clin Immunol. 2012;32:454–66. Wolach B, Gavrieli R, Roos D, Berger-Achituv S. Lessons learned from phagocytic function studies in a large cohort of patients with recurrent infections. J Clin Immunol. 2012;32:454–66.
17.
go back to reference Hsu AP, Sowerwine KJ, Lawrence MG, Davis J, Henderson CJ, Zarember KA, Garofalo M, Gallin JI, Kuhns DB, Heller T, Milner JD, Puck JM, Freeman AF, Holland SM: Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol 2013. Hsu AP, Sowerwine KJ, Lawrence MG, Davis J, Henderson CJ, Zarember KA, Garofalo M, Gallin JI, Kuhns DB, Heller T, Milner JD, Puck JM, Freeman AF, Holland SM: Intermediate phenotypes in patients with autosomal dominant hyper-IgE syndrome caused by somatic mosaicism. J Allergy Clin Immunol 2013.
18.
go back to reference Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, et al. Calcineurin inhibitors suppress cytokine production from memory t cells and differentiation of naive t cells into cytokine-producing mature T cells. PLoS One. 2012;7:e31465. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, et al. Calcineurin inhibitors suppress cytokine production from memory t cells and differentiation of naive t cells into cytokine-producing mature T cells. PLoS One. 2012;7:e31465.
19.
go back to reference Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced t(h)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced t(h)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol. 2008;122:181–7.
Metadata
Title
Variable Clinical expressivity of STAT3 Mutation in Hyperimmunoglobulin E Syndrome: Genetic and Clinical Studies of Six Patients
Authors
Ofir Wolach
Taco Kuijpers
Josef Ben-Ari
Ronit Gavrieli
Neta Feinstein-Goren
Marielle Alders
Ben Zion Garty
Baruch Wolach
Publication date
01-02-2014
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 2/2014
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-014-9988-4

Other articles of this Issue 2/2014

Journal of Clinical Immunology 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.